PURPOSE: We conducted a systematic review and meta-analysis to determine the effectiveness and safety of anti-tumor necrosis factor-alpha (TNF-α) agents in the treatment of Behcets' disease (BD)-associated uveitis. METHOD: Three electronic databases, Embase, MEDLINE, and the Cochrane Library, were searched for eligible papers focusing on the anti-TNF-α agents treatment in BD-associated uveitis with at least 6 months follow-up time. A systematic review and meta-analysis was conducted on selected papers with appropriate clinical and methodological homogeneity. The effectiveness outcomes included inflammation remission, visual acuity (VA) improvement, central macular thickness (CMT) decrease, corticosteroid (CS)-sparing effects, and the safety outcomes included minor and severe drug-related adverse events (AEs). RESULT: From Jan 2010 to Dec 2019, there were 504 records produced in total, in which 18 clinical trials were selected for meta-analysis (15 trials were retrospective studies, and 3 were prospective studies). The number of patients in each study ranged from 11 to 163 and the mean follow-up time from 0.9 to 6.44 years. During the follow-up, the pooled inflammation remission rate was 68% with a 95% confidence interval (CI) of 0.59-0.79, VA improvement rate was 60% (95% CI 0.47-0.77), CMT decrease was 112.70 μm (95% CI 72.8-153.0 μm). The proportions of patients who had CS-suspended and CS-tapered reached 38% (95% CI 0.23-0.65) and 34% (95% CI 0.16-0.70), respectively. The severe AEs were reported but not common, which included severe infusion reactions, pneumonia, bacteremia, tuberculosis, melanoma, and lymphoma. CONCLUSION: Anti-TNF-α agents treatment has high effectiveness including efficient inflammation remission, satisfactory VA improvement, obvious CMT reduction, and significant CS-sparing effects. Although some drug-related AEs were reported, the incidence of severe AEs was acceptable. Anti-TNF-α agents treatment is a promising option for controlling BD-associated uveitis.
PURPOSE: We conducted a systematic review and meta-analysis to determine the effectiveness and safety of anti-tumor necrosis factor-alpha (TNF-α) agents in the treatment of Behcets' disease (BD)-associated uveitis. METHOD: Three electronic databases, Embase, MEDLINE, and the Cochrane Library, were searched for eligible papers focusing on the anti-TNF-α agents treatment in BD-associated uveitis with at least 6 months follow-up time. A systematic review and meta-analysis was conducted on selected papers with appropriate clinical and methodological homogeneity. The effectiveness outcomes included inflammation remission, visual acuity (VA) improvement, central macular thickness (CMT) decrease, corticosteroid (CS)-sparing effects, and the safety outcomes included minor and severe drug-related adverse events (AEs). RESULT: From Jan 2010 to Dec 2019, there were 504 records produced in total, in which 18 clinical trials were selected for meta-analysis (15 trials were retrospective studies, and 3 were prospective studies). The number of patients in each study ranged from 11 to 163 and the mean follow-up time from 0.9 to 6.44 years. During the follow-up, the pooled inflammation remission rate was 68% with a 95% confidence interval (CI) of 0.59-0.79, VA improvement rate was 60% (95% CI 0.47-0.77), CMT decrease was 112.70 μm (95% CI 72.8-153.0 μm). The proportions of patients who had CS-suspended and CS-tapered reached 38% (95% CI 0.23-0.65) and 34% (95% CI 0.16-0.70), respectively. The severe AEs were reported but not common, which included severe infusion reactions, pneumonia, bacteremia, tuberculosis, melanoma, and lymphoma. CONCLUSION: Anti-TNF-α agents treatment has high effectiveness including efficient inflammation remission, satisfactory VA improvement, obvious CMT reduction, and significant CS-sparing effects. Although some drug-related AEs were reported, the incidence of severe AEs was acceptable. Anti-TNF-α agents treatment is a promising option for controlling BD-associated uveitis.
Authors: Gulen Hatemi; Robin Christensen; Dongsik Bang; Bahram Bodaghi; Aykut Ferhat Celik; Farida Fortune; Julien Gaudric; Ahmet Gul; Ina Kötter; Pietro Leccese; Alfred Mahr; Robert Moots; Yesim Ozguler; Jutta Richter; David Saadoun; Carlo Salvarani; Francesco Scuderi; Petros P Sfikakis; Aksel Siva; Miles Stanford; Ilknur Tugal-Tutkun; Richard West; Sebahattin Yurdakul; Ignazio Olivieri; Hasan Yazici Journal: Ann Rheum Dis Date: 2018-04-06 Impact factor: 19.103
Authors: M Santos Lacomba; C Marcos Martín; J M Gallardo Galera; M A Gómez Vidal; E Collantes Estévez; R Ramírez Chamond; M Omar Journal: Ophthalmic Res Date: 2001 Sep-Oct Impact factor: 2.892
Authors: Vanesa Calvo-Río; Ricardo Blanco; Emma Beltrán; Juán Sánchez-Bursón; Marina Mesquida; Alfredo Adán; María Victoria Hernandez; Marisa Hernandez Garfella; Elia Valls Pascual; Lucía Martínez-Costa; Agustí Sellas-Fernández; Miguel Cordero Coma; Manuel Díaz-Llopis; Roberto Gallego; David Salom; José L García Serrano; Norberto Ortego; José M Herreras; Alejandro Fonollosa; Angel M García-Aparicio; Olga Maíz; Ana Blanco; Ignacio Torre; Cruz Fernández-Espartero; Vega Jovani; Diana Peiteado-Lopez; Esperanza Pato; Juan Cruz; Carlos Fernández-Cid; Elena Aurrecoechea; Miriam García; Miguel A Caracuel; Carlos Montilla; Antonio Atanes; Félix Francisco Hernandez; Santos Insua; Senén González-Suárez; Amalia Sánchez-Andrade; Fernando Gamero; Luis Linares; Fredeswinda Romero-Bueno; A Javier García; Raquel Almodovar; Enrique Minguez; Carmen Carrasco Cubero; Alejandro Olive; Julio Vázquez; Oscar Ruiz Moreno; Fernando Jiménez-Zorzo; Javier Manero; Santiago Muñoz Fernández; Javier Rueda-Gotor; Miguel A González-Gay Journal: Rheumatology (Oxford) Date: 2014-07-04 Impact factor: 7.580
Authors: Eric B Suhler; Careen Y Lowder; Debra A Goldstein; Tracy Giles; Andreas K Lauer; Paul A Kurz; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Howard H Tessler; Justine R Smith; James T Rosenbaum Journal: Br J Ophthalmol Date: 2013-02-02 Impact factor: 4.638
Authors: Gabriele Simonini; Katie Druce; Rolando Cimaz; Gary J Macfarlane; Gareth T Jones Journal: Arthritis Care Res (Hoboken) Date: 2014-07 Impact factor: 4.794
Authors: Sultan Al Rashidi; Abdullah Al Fawaz; Dustan Kangave; Ahmed M Abu El-Asrar Journal: Ocul Immunol Inflamm Date: 2013-06-04 Impact factor: 3.070